District Court Orders Mexican FDA to Grant Cannabis Authorizations to Xebra
On December 8, 2022, Xebra announced that the Mexican Health Regulatory Agency (the Mexican FDA equivalent) (the "COFEPRIS"), had formally notified Xebra's Mexican subsidiary, Desart MX, SA de CV ("Xebra Mexico"), with a resolution in which it claimed to have complied with the Supreme Court mandate to grant Xebra cannabis authorizations.
- On December 8, 2022, Xebra announced that the Mexican Health Regulatory Agency (the Mexican FDA equivalent) (the "COFEPRIS"), had formally notified Xebra's Mexican subsidiary, Desart MX, SA de CV ("Xebra Mexico"), with a resolution in which it claimed to have complied with the Supreme Court mandate to grant Xebra cannabis authorizations.
- A District Court judge has now reviewed the COFEPRIS resolution and ruled in favor of Xebra Mexico, outright rejecting its scope and language as materially insufficient and upholding Xebra's irrefutable legal rights granted by the Supreme Court.
- Thus, the judge ordered the COFEPRIS to issue the full and proper authorizations within 3 business days.
- Due to many Mexican government offices closing during the holiday season, Xebra anticipates the process of issuing the authorizations to continue into January 2023.